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1. Introduction
Hepatitis C virus infection represents the most common cause of chronic hepatitis with
potential evolution into cirrhosis and hepatocellular carcinoma [1]. The infected population
appears heterogeneous for age, modalities of infection, and disease duration [2]. To date the
standard of care of treatment (SOC) has been pegylated interferon alpha 2a or alpha 2b
associated with ribavirin. The main goal of the therapy is the achievement of a sustained
virological response (SVR) defined as undetectable HCV RNA 24 weeks after stopping
treatment.
Several factors influence therapeutic schedules. First of all, HCV genotype 1 (G1) and 4 require
longer treatment as compared to G2 and G3.
Early virologic negativization after starting therapy, together with virus genotype, are the most
important predictors of sustained virological response.
The absence of a virologic response by week 12 has the highest negative predictive value
for all genotypes suggesting that HCV RNA disappearance should be achieved as soon as
possible [3].
Many other factors such as age, gender, degree of fibrosis and viral load influence SVR; more
recently, the single nucleotide polymorphism (SNPs) of the IL28B gene has been demonstrated
to be a good predictor of response [4].
The analysis of large cohorts demonstrates that, even in patients treated for 48 weeks, almost
half of G1 infected patients does not reach a SVR, as compared to 20% of G2/3 [5].
Treatment failure is defined on the basis of the virological response to treatment, as follows:
a. null responders, if the reduction of HCV RNA is less than 1 log10 at week 12 of therapy;
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b. virological nonresponse is considered when the serum HCV RNA level remains above
the limit of detection throughout treatment and is defined as less than 2 log10 decline in
HCV RNA between baseline and week 12;
c. partial responders if the reduction of HCV RNA is at least 2 log10 at 12 weeks but it is still
detectable at week 24;
d. relapsers if HCV RNA decreases and remains below the limit of detection (<50 IU/mL)
during treatment but becomes detectable after cessation of treatment [6].
HCV infection is often characterized by extrahepatic associated diseases. HCV is considered
a stimulus for B-cell clonal expansion underlying benign and malignant B-cell dyscrasias
including a subgroup of B-cells non Hodgkin’s lymphomas. In this context, we must consider
that HCV infection is also characterized by several extrahepatic manifestations. The most
common and well characterized is mixed cryoglobulinemia. This condition, as well as some
B-cell non Hodgkin’s lymphomas, is the result of B-cell clonal expansion due to viral persis‐
tence [7].
Accordingly, the treatment of HCV chronic infection should be addressed not only to the
treatment of chronic liver disease, but also to the prevention of HCV-associated diseases.
It is estimated that 25% of HCC worldwide is related to HCV [8].
If the rate of response to antiviral therapy increases to 80%, over the next ten years, the
treatment of half of HCV-infected persons would reduce cirrhosis by 15%, hepatocellular
carcinoma by 30% and death for liver disease by 34%. [9].
The application of the most effective therapy should be a common strategy to block perma‐
nently viral replication and avoid the progression to cirrhosis and the development of
hepatocellular carcinoma.
Boceprevir and telaprevir are HCV protease inhibitors, recently approved for antiviral therapy
in HCV infected patients, are effective to control the viral replication.
2. Target of protease inhibitors
HCV genome is a single strand RNA of 9000-9100 nucleotide encoding for three stuctural (C,
E1, E2), seven non structural (xlink, NS3, NS4A, NS4B, NS5A, NS5B, p7) and F proteins whose
role is unknown [10] (Fig 1).
HCV replicative cycle involves the translation of the HCV RNA into a single polyprotein that
is subsequently cleaved to obtain every single structural and non structural proteins.
NS3 is a serine protease while NS4 serves as cofactor. NS3 and NS4A must be assembled in
order to become active in catalyzing the cleavage of the other NS proteins from the HCV
polyprotein at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions, a condi‐
tion required for viral replication.
Practical Management of Chronic Viral Hepatitis168
HCV virions turn over rapidly (with a half-life of about 3 h), and up to 1012 viruses are produced
per day in an infected person [11].
Figure 1. Genomic organization of hepatitis C polyprotein. The HCV genome (about 9000 nucleotides) is translated in
a single polypeptide of 3000 aminoacids. Then the polypeptide is cleved to produce ten proteins whose role is ex‐
plained below. During an alternative splicing within the core, a new protein (F protein) can be produced (this one not
represented) (From :Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting
antiviral agents. J Viral Hepat 2012 Jul;19(7):449-464)..
Boceprevir and Telaprevir link to NS3/NS4A enzymatic complex in a covalent and reversible
manner to disrupt the processing of the HCV polyprotein.
Even if the protease inhibitors are potent antiviral agent, their administration without
interferon and ribavirin is characterized by rapid selection of resistant variants of the virus [12].
Accordingly boceprevir and telaprevir need to be administered in a regimen with pegylated-
interferon and ribavirin, commonly named “triple therapy”.
During the initial 2 weeks of triple therapy the viral load decline is rapid and unaffected by
ribavirin. However, beyond 2 weeks, viral breakthrough occurs if ribavirin is not administered.
After 12 weeks, breakthrough occurs in 24% of patients treated with peg-interferon and
telaprevir.
Ribavirin also affects the rate of viral relapse. In regimens without ribavirin, relapse occurs in
48% of patients as compared to 14-30% of patients treated with ribavirin [13].
3. Management of antiviral therapy in naive patients
Three trials (SPRINT-2, ADVANCE, ILLUMINATE) examined the efficacy of boceprevir and
telaprevir in naïve patients.
Telaprevir obtained a SVR rate of 75% as compared to 44% of the SOC with peg-interferon
plus ribavirin.
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The schedule includes triple therapy (telaprevir + peg-interferon + ribavirin) for the first 12
weeks and peg-interferon+ribavirin for additional 36 weeks (fig 3). Telaprevir is administered
at the dose of 750 mg thrice daily.
The tablets should be taken with high fat (>20 g) meal or snack for optimal adsorption (table 2).
Patients with undetectable HCV RNA at week 4 (rapid virological response, RVR) and 12
(extended rapid virological response, eRVR) can stop therapy after 24 weeks of treatment
(response-guided therapy, RGT) [14].
In the contrast, telaprevir should be stopped when:
a. HCV RNA is more than 1000 UI/ml at week 4 or 12 or
Figure 2. The nucleocapsid of the HCV genome is surrounded by an envelope that facilitates attachment and penetra‐
tion into host cells. Upon entry into the host cell by endocytosis, the virus undergoes undergoes a fusion and uncoat‐
ing step. Its RNA is translated into a polyprotein of approximately 3,000 aminoacids that is processed by cellular and
viral proteases (including NS3) to yield structural and non structural proteins. Boceprevir and telaprevir block the poly‐
protein processing by stopping activity of NS3/NS4A complex, which has protease activity on the polypeptide (From
Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-938;
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment--finding the
right path. Nat Rev Drug Discov 2007 Dec;6(12):991-1000).
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b. HCV RNA is detectable at week 24
Boceprevir was differently studied in black and non-black populations.
The SVR rate was 53% and 68% in black and not-black population, respectively.
Boceprevir requires a “lead-in” phase with peg-interferon and ribavirin for 4 weeks and triple
therapy (boceprevir + peg-interferon + ribavirin) for 24 or 32 weeks and again a dual therapy
with peg-interferon and ribavirin for the last 4 weeks (fig 4).
The lead-in in phase is useful in naïve patients to assess the responsiveness to peg-interferon
and ribavirin.
In fact, lower SVR rates and development of boceprevir-resistant mutants are more common
in patients with HCV RNA reduction less than 1 log10 at week 4 independently from the
treatment scheme [15].
The recommended dose of boceprevir is 800 mg thrice daily. Meal seems not influence the
absorption as much as observed in telaprevir regimens.
In patients with RVR after the “lead-in” phase, SOC is still recommended since SVR is observed
in 88% after 48 weeks of therapy [16].
Accordingly to the response-guided therapy, RGT, patients treated with boceprevir with
undetectable HCV RNA at weeks 8 and 24 can stop therapy after 36 weeks of treatment.
If HCV RNA is detectable at week 8, the treatment should continue to 48 weeks.
Boceprevir should be stopped when:
a. HCV RNA is more than 100 UI/ml at week 12 or
b. HCV RNA is detectable at week 24.
4. Management of antiviral therapy in null responders
Retreatment of null responders with peg-interferon and ribavirin is effective in less than 5%
of patients [17].
Telaprevir increases SVR to 31%.
The schedule requires 48 weeks of treatment, with the first 12 weeks of triple and the remaining
36 weeks with peg-interferon and ribavirin.
The stopping rules are the same of naïve patients.
Boceprevir trials did not include null responders and, to date, it is not recommended in such
patients.
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5. Management of antiviral therapy in partial responders
Retreatment of partial responders with SOC is effective in 7-15% of patients [17, 18].
Triple therapy with boceprevir or telaprevir may increase the rate of SVR to 52% and 57%,
respectively.
Response-guided therapy is not recommended since 48 weeks are commonly requested.
6. Management of antiviral therapy in relapsers
Retreatment of relapsers with SOC induces a SVR in less than 1/3 of patients [17, 18].
Telaprevir is administered for the first 12 weeks and SOC for the further 36 weeks with a SVR
rate of 86%.
Boceprevir requires the “lead-in” phase of SOC and triple therapy for the additional 44 weeks
with a SVR of 75%.
If HCV RNA is not detected at weeks 8 and 24, the therapy may be stopped at week 32.
STUDY Drug Population Treatment arms InterventionSVR
SOC
SVR Main findings
SPRINT-2 Boceprevir Naive
Black-RGT
Black- 48 week
Non Black RGT
Non Black- 48 week
42%
53%
67%
68%
23%
40%
RGT therapy as
effective as 48
weeks of therapy for
non black patients.
About 50% of
patients elegible for
RGT
ADVANCE Telaprevir Naive
T8 (pooled 24- and 48-
week total therapy)
T12 (pooled 24- and
48-week total therapy)
69%
75% 44%
12-week telaprevir
regiment preferable
to 8-week regimen
ILLUMINATE Telaprevir Naive
T12 overall
eRVR+24-week
therapy
eRVR+48-week
therapy
75%
92%
88%
N/A
24-week total
therapy for eRVR
patients non inferior
to 48 weeks of
therapy. About 75%
of patients eligible
for shorter duration
of therapy
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STUDY Drug Population Treatment arms InterventionSVR
SOC
SVR Main findings
RESPOND-2 Boceprevir Treatmentexperienced
RGT- prior relapser
RGT-Prior non
responder
48 weeks-relapsers
48week-non
responders
69%
40%
75%
52%
29%
7%
Null responders
excluded. Relapsers
had similar
outcomes as naive
population
REALIZE Telaprevir Treatmentexperienced
T12 (48-week total
therapy)
Prior relapsers
Prior partial
responders
Prior null responders
86%
57%
31%
24%
15%
5%
Relapers had similar
outcomes as naive
population
Table 1. Summary of phase 3 clinical trials for boceprevir and telaprevir.eRVR, extended rapid virologic response; RGT,
response guided therapy; SOC, standard of care; SVR, sustained virologic response; T8, 8-week telaprevir arm; T12, 12-
week telaprevir arm (From: Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for
hepatitis C virus. Gastroenterology 2012 May;142(6):1314-1323).
Figure 3. Telaprevir schedule. In naïve and prior relapser patients telaprevir should be administered for the first 12
weeks and peg-interferon plus ribavirin for 12 or 36 weeks additional. In case of eRVR (HCV RNA not detected at week
4 and 12 the treatment may be stopped after 24 weeks. If HCV RNA is still detected at week 12, peg-interferon and
ribavirin should be continued for additional 36 weeks. In any case if HCV RNA is detectable at week 24 or results >
1000 UI/ml between 4 and 12 weeks, the treatment should be stopped. RBV, ribavirin; eRVR, extended rapid virologic
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response (From: Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C
virus. Gastroenterology 2012 May;142(6):1314-1323.)
7. Management of side effect of antiviral therapy
Even if only 2% are severe, almost all patients treated with boceprevir or telaprevir report side
effects. Among all, anaemia is the most common, occurring in 50% of patients treated with
protease inhibitor as compared to 20% of peg-interferon and ribavirin.
Examples of food containing at least 20 g of fat
Bagel with cream cheese
½ cup of nuts
3 tablespoons of peanut butter
1 cup of ice cream
60 g of American or cheddar cheese
60 g of potato chips
½ cup of trail mix
33 g of granola
3 slices of homemade French toast
2 cups 3.3% whole milk
60 g of chocolate candy bar with almonds or peanuts
Two 60 g plain doughnuts
1 slice pecan pie
1 medium avocado
100 g of lean hamburger in bun
100 g of salami
4 slices of bologna
100 g of broiled pork chop
Three 100 g sausage patties
2 cup chow mein noodles
200 g of fried chicken breast
2 small roasted chicken legs
Table 2. Food containing at least 20 g of fat (From: Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and
management of drug interactions with boceprevir and telaprevir. Hepatology 2012 May;55(5):1620-1628.)
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Blood count should be monitored during the first 4 weeks to identify those who will need
support.
In patients treated with boceprevir, SVR has been observed more frequently in those who
develop anaemia [19].
Administration of subcutaneous alpha-erythropoietin 40.000 UI once a week is effective in
controlling anaemia induced by peg-interferon and ribavirin as well as protease inhibitors
trying to maintain the blood level around 100 g/L.
If ineffective, ribavirin may be reduced and blood transfusion considered.
It has been reported that, in triple therapy regimen, ribavirin may be safely reduced without
affecting the SVR rate.
When this strategy is insufficient and anaemia becomes more severe, blood transfusion is
required.
Neutropenia occurs in 70-80% of patients treated with triple therapy and this is more com‐
monly observed in those developing anaemia [20].
Figure 4. Boceprevir schedule. A “lead in” phase (4 weeks of peg-interferon and ribavirin before the beginning of the
triple therapy) is considered for all patients. In naïve patients boceprevir should be administered for a minimum of 24
weeks. If HCV RNA is negative at week 8 and 24 all drugs must be stopped at week 28. If HCV RNA is detectable at
week 8 o 24, boceprevir should be administrated for 32 weeks and peg-interferon plus ribavirin for additional 12
weeks.In prior relapsers and partial responders boceprevir should be administered for 32 weeks and peg-interferon
plus ribavirin for additional 12 weeks. In any case, if HCV RNA is detectable at week 24 or HCV RNA is >100 UI/ml at
week 12, the treatment should be stopped (From: Barritt AS, Fried MW. Maximizing opportunities and avoiding mis‐
takes in triple therapy for hepatitis C virus. Gastroenterology 2012 May;142(6):1314-1323.).
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Filgrastim 30 MU subcutaneous one to three times a week usually maintains the count of
neutrophils > 1000/µL.
Boceprevir Telaprevir
Complete blood
count
Baseline
week 2 and 4
weekly for the first month of triple therapy
(from week 4 to 8)
then monthly or
as necessary
Baseline
weekly for the first month of triple therapy
Every three weeks until the end of triple
then monthly during the left dual therapy
or
as necessary
Liver function tests
Baseline
week 4-6 and 8
then monthly
Baseline
Week 2-4 and 8
Then monthly
Serum electrolytes
Creatinine
Uric acid
Baseline
week 2
then monthly
Baseline
week 2
then monthly
TSH
Baseline
week 12 and 24
then as necessary
Baseline
week 12 and 24
then as necessary
Cholesterol
Tryglicerides
Baseline
week 12 and 24
then as necessary
Baseline
week 12 and 24
then as necessary
Table 3. Proposal for blood monitoring during triple therapy
HEMATOLOGICAL SIDE EFFECT CHANGE DURING THERAPY
Anemia
< 100 g/L Erythropoietin 40.000 UI once a week
< 90 g/L Ribavirin dose reduction + Erythropoietin
< 80 g/L Blood transfusion
Thrombocytopenia
≥ 100.000/µL No change
≥ 50.000/µL Weekly control then monthly
< 50.000/µL Peg-interferon dose reduction
< 25.000/µL Stop therapy
Neutropenia
< 1000/µL Filgrastim 30 MU once/ twice/ thrice a week
< 750/µL Peg-interferon dose reduction
Table 4. Management of haematological side effects during triple therapy.
The adverse effects described during peg-interferon and ribavirin therapy such as rush, flu
like and gastrointestinal symptoms are more commonly observed during triple therapy.
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Fatigue, nausea, dysgeusia, chills, insomnia, alopecia, diarrhoea, decreased appetite, irritabil‐
ity, vomiting, arthralgia, dizziness, dry skin rash, asthenia, dyspnoea on exertion are more
common during boceprevir [21]. In particular, dysgeusia affects almost 50% of patients.
Telaprevir induces hyperuricemia, fatigue, pruritus, diarrhoea, vomiting, haemorrhoids,
anorectal discomfort, dysgeusia and anal pruritus relative to patients on standard of care.
Cutaneous rash is the less tolerated side effect of telaprevir. Fortunately, more than 90% of
such events is mild or moderate and does not progress. Discontinuation occurs only in 6% of
cases [22]. Oral antihistamines or a topical steroid is effective in controlling symptoms.
Moderate rash may associate with pruritus or mucosal involvement. When more than 50% of
the body surface is involved or vesicles, bullae or ulceration develop, rash is considered severe
and telaprevir should be stopped; peg-interferon and ribavirin can be continued for additional
6-7 days. If the rash does not improve, all drugs should be stopped and hospitalization and
appropriate therapy is required [23].
Haemorrhoids, anal pruritus, anorectal discomfort and anal burning observed during
telaprevir may be managed with topic steroid or local lidocaine.
Life threatening or systemic reaction (Steven-Johnson syndrome, drug reaction with eosino‐
philia and systemic symptoms – DRESS, erythema multiforme-EM) are rarely observed (refer
to the specific chapter for details).
Figure 5. Estimating body surface area (BSA: body surface area) (From: Hezode C. Boceprevir and telaprevir for the
treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012 Feb;32 Suppl 1:32-38)
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8. Drug interactions
Boceprevir and telaprevir are metabolized via the cytochrome P4503A pathway. They are
potent inhibitors of CYP3A4 and also substrates and inhibitors of the drug transporter P-
glycoprotein (P-gp).
Boceprevir and telaprevir availability depends on Child-Pugh but not on renal function.
Concentration of boceprevir in serum increases of 30% and 45-60% in patients with Child Pugh
B and C, respectively.
Telaprevir is reduced of about 10-15% and 50% in Child Pugh B and C, respectively. Protease
inhibitors greatly impact the metabolism of HMG-CoA reductase inhibitors.
Simvastatin and lovastatin are not recommended in patients treated with boceprevir or
telaprevir. Atorvastatin should be avoided when telaprevir is administered and a lowest dose
should be selected in boceprevir treated patients. Pravastatin is metabolized by other pathway
and the risk of interaction is not completely defined. Rosuvastatin may be safely administered,
even if it has not been specifically addressed in the trials.
STATINS Use during Boceprevir Use during Telaprevir
Simvastatin NO NO
Atorvastatin POSSIBLE (USE THE LOWEST DOSE) NO
Lovastatin NO NO
Pravastatin YES NO DATA
Rosuvastatin POSSIBLE POSSIBLE
Table 5. Potential association between protease inhibitors and statins.
Both boceprevir and telaprevir may reduce contraceptive efficacy of ethinyl estradiol. More‐
over, boceprevir can increase plasmatic level of drosperidone while telaprevir reduces
norethindrone.
Benzodiazepines (triazolam, alprazolam, flurazepam) may be greatly affected by protease
inhibitors and should be avoided until new data are available.
Both boceprevir and telaprevir increase metabolism of escitalopram and its effect may be
reduced.
Zolpidem concentration is reduced by of 42% in patients treated with telaprevir as well as
trazodone.
Boceprevir and telaprevir reduce the clearance of cyclosporine and tacrolimus. The exposure
to cyclosporine increases 4-fold with telaprevir and 3-fold with boceprevir, while tacrolimus
plasmatic concentration increases 70-fold after telaprevir administration and 17-fold after
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boceprevir. On the other hands, immunosuppressive drugs seen not change boceprevir and
telaprevir metabolism.
DRUGS TO BE AVOIDED
INCREASED
CONCENTRATION OF
CONCOMITANT MED OR
HCV PI
REDUCED
CONCENTRATION OF
CONCOMITANT MED OR
HCV PI
Alpha-1 adrenoreceptor
antagonist Alfuzosin
Doxazosin
Terazosin
Tamsulosin
Silodosin
Anticonvulsant
Carbamazepime
Phenobarbital
Phenytoin
Antifungals
Ketoconazole
Itraconazole
Posaconazole
Voriconazole
Antimicrobials ClarithromycineErythromycin
Antimycobacterials RifampinRifapentine Rifabutin
Antiretroviral drugs
Lopinavir (TPV)
Darunavir (TPV)
Fosamprenavir (TPV)
Efavirenz (BOC)
Efavirenz (TPV)*
Benzodiazepines and sleep
aids
Flurazepam
Quazepam
Triazolam
Oral midazolam
Alprazolam
Trazodone
Cardiovascular
Amiodarone
Bosentan
Dofetilide
Flecainide
Lidocaine
Propafenone
Quinidine
sildenafil and tadalafil for
pulmonary arterial
hypertension
Calcium-channel blockers
Digoxin
Carvedilol
Nabivolol
Irbesartan
Losartan
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DRUGS TO BE AVOIDED
INCREASED
CONCENTRATION OF
CONCOMITANT MED OR
HCV PI
REDUCED
CONCENTRATION OF
CONCOMITANT MED OR
HCV PI
Ergot derivatives
Dihydroergotamine
Ergonovine
Ergotamine
Methylergonovine
Herbal products St. John’s wort
HMG-CoA reductase
inhibitors
Lovastatin
Simvastatin
Atorvastatin (TPV)
Atorvastatin (BOC)
Pravastatin
Rosuvastatin
Immunosuppressant TacrolimusSirolimus Cyclosporine
Oral contraceptives Drosperinone (BOC) Ethynil estradiol
Respiratory Fluticasonesalmeterol
Second-generation
antipsycotic Quetiapine
Iloperidone
aripiprazole
Interaction unique to one of the HCV protease inhibitors are indicated in parentheses (e.g. TPV or BOC).
Abbreviation: Med, medication; PI, protease inhibitor; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A.
*A higher dose of TPV [1,120 mg every 8 hours) has been studied with efavirenz with promising preliminary rates of SVR.
( From: Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and
telaprevir. Hepatology 2012 May;55[5]:1620-1628]
Table 6. Summary of drugs to avoid and drugs to use with caution in combination with boceprevir (BOC) and
telaprevir (TPV).
9. Triple therapy in cirrhotic and liver transplant patients
Cirrhosis increases morbidity and mortality and reduces SVR [24].
Clinical efficacy in cirrhosis has been investigated in phase 3 trials (ADVANCE, ILLUMI‐
NATE, REALIZE, RESPOND-2, SPRINT-2).
SVR is reached in 33% - 46% after 48 weeks of peg-interferon and ribavirin. [25, 26]
The addiction of a protease inhibitor improves the SVR to 50% [26]. In these cases, 48 weeks
of treatment are commonly required.
In relapsers, the addition of a protease inhibitor increases SVR to 87%.
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In partial responders SVR rate is lower (34% with triple therapy and 20% in peg-interferon and
ribavirin schedule)
There are no benefits in cirrhotic null responders with by using telaprevir (14% vs 10%) [27].
The  relapse  rate  remains  high  and  side  effects  are  too  frequently  observed  in  cirrhotic
patients [24].
Until now, protease inhibitors are not approved for patients with liver transplantation for the
interactions with immunosuppressive drugs [12].
10. Genetics and triple therapy
Interleukin 28B (IL28B) polymorfisms impacts the response to peg-interferon and ribavirin.
TRIPLE THERAPY rs 12979860
Boceprevir
SVR
C/C C/T T/T
80-82% 65-71% 55-59%
Telaprevir
SVR
C/C C/T T/T
90% 71% 73%
(From: Thompson AJ. Genetic factors and hepatitis C virus infection. Gastroenterology 2012 May;142(6):1335-1339)
Table 7. Response rate according to IL28B genotype in treatment-naive G1 HCV patients receiving triple therapy
Peg-interferon plus ribavirin Polymorphism
CAUCASIAN (n=1171) rs 12979860
SVR
C/C C/T T/T
69% 33% 27%
AFROAMERICANS (n=300) rs 12979860
SVR
C/C C/T T/T
48% 15% 13%
T/T genotype is associated with poor response.
The response is lower in Afro-Americans.
SVR, sustained virological response.
(From: Thompson AJ. Genetic factors and hepatitis C virus infection. Gastroenterology 2012 May;142(6):1335-1339)
Table 8. Response rate according to IL28B genotype (rs12979860) in treatment-naive North American G1 HCV
patients receiving 48 week peg-interferon alpha plus ribavirin. Genotype C/C achieves SVR in 69% (good response).
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The rs12979860 polymorphism has three possible genotypes (C/C, C/T, T/T), with C/C showing
2.5 or grater rate of SVR during therapy with peg-interferon and ribavirin.
The rs 8099917 polymorphisms has G/G, G/T, T/T genotypes. T/T genotype associates with
higher SVR.
In G1 infected naive-patients eligible for antiviral therapy, the response after the “lead-in”
phase and IL28B genotype are the most powerful predictors of response. In selective cases,
when the benefit versus risk ratio is difficult to define IL28 may support the final decision.
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